What human biologic treatments are recommended for a pediatric patient with recurrent Clostridioides difficile infection?

Human Biologics for Recurrent C. difficile in Pediatric Patients

For pediatric patients with recurrent Clostridioides difficile infection, fecal microbiota transplantation (FMT) is the primary human biologic therapy recommended after failure of standard antibiotic treatments, while bezlotoxumab (a monoclonal antibody against toxin B) has emerging evidence in high-risk pediatric populations but was discontinued in January 2025. 1

Treatment Algorithm for Recurrent CDI in Children

First Recurrence (Non-severe)

• Either metronidazole (7.5 mg/kg/dose tid or qid, max 500 mg) OR vancomycin (10 mg/kg/dose qid, max 125 mg) for 10 days 1
• Weak recommendation due to limited pediatric-specific data

Second or Subsequent Recurrence

The IDSA/SHEA guidelines provide three options with equal standing 1:

1. Vancomycin tapered and pulsed regimen:

   • 10 mg/kg (max 125 mg) qid × 10-14 days
   • Then 10 mg/kg (max 125 mg) bid × 1 week
   • Then 10 mg/kg (max 125 mg) daily × 1 week
   • Then 10 mg/kg (max 125 mg) every 2-3 days × 2-8 weeks

2. Vancomycin followed by rifaximin:

   • Vancomycin 10 mg/kg qid × 10 days
   • Followed by rifaximin 400 mg tid × 20 days
   • Critical caveat: Rifaximin lacks FDA approval and established pediatric dosing for children <12 years 1

3. Fecal microbiota transplantation (discussed below)

Fecal Microbiota Transplantation (FMT)

FMT should be considered for pediatric patients with multiple recurrences following standard antibiotic treatments (weak recommendation, very low quality evidence). 1

Key Evidence Points:

• Adult data shows cure rates of approximately 81% in RCTs, with meta-analyses of case series showing similar efficacy 2
• Limited pediatric case reports and series demonstrate effectiveness via nasogastric tube or colonoscopy with follow-up periods up to 16 months 1
• Most pediatric cases used parental donors (mother or father) 1
• Survey data indicates 18% of pediatric infectious disease physicians have recommended FMT, most commonly for third or later recurrence 1
• Recent case report demonstrates successful use even in fulminant CDI with toxic megacolon in a critically ill pediatric patient 3

Important Safety Considerations:

• Procedure-related risks from nasogastric tube or colonoscopy administration
• Potential transmission of resistant organisms and blood-borne pathogens requiring rigorous donor screening 4
• Theoretical long-term risks including metabolic or immune-based disorders 1
• One study found sustained acquisition of procarcinogenic bacteria post-FMT in 4 of 11 pediatric patients (6 with underlying IBD) 4
• Comprehensive donor screening protocols are essential (see Box 3 and 4 in 4 for detailed requirements)

Bezlotoxumab (Monoclonal Antibody)

Bezlotoxumab is a human monoclonal antibody directed against C. difficile toxin B that was approved as adjunctive therapy for adults at high risk for recurrence. 1

Pediatric Evidence:

• Multi-institutional case series in pediatric stem cell transplant recipients showed bezlotoxumab was safe and effective when used with antibiotics for recurrent/chronic CDI 5
• No increased adverse events, no impact on graft-versus-host disease management, and safe in peri-transplantation period 5
• Studies in pediatric populations are ongoing 6

Critical Limitation:

Bezlotoxumab was discontinued in January 2025 for unknown reasons, making it no longer available for clinical use despite promising pediatric data 5

Clinical Decision Framework

For a pediatric patient with recurrent CDI, follow this approach:

1. Define the recurrence number:

   • First recurrence: Standard antibiotic course (vancomycin or metronidazole)
   • Second recurrence: Consider tapered/pulsed vancomycin OR proceed to FMT
   • Third or greater recurrence: Strongly consider FMT

2. Assess patient-specific factors:

   • Immunosuppression status (higher risk, may benefit from earlier FMT consideration)
   • Underlying conditions (IBD, malignancy, transplant recipients)
   • Previous antibiotic exposures and responses
   • Severity of current episode

3. For FMT candidates:

   • Ensure failure of at least 2 appropriate antibiotic courses (3 total CDI episodes) 1
   • Identify appropriate donor with comprehensive screening 4
   • Select administration route (colonoscopy vs nasogastric tube) based on institutional expertise and patient factors
   • Counsel families on theoretical risks and limited long-term pediatric data

Common Pitfalls to Avoid

• Do not use metronidazole for multiple recurrences - associated with neuropathies with prolonged exposure and inferior outcomes 1
• Do not delay FMT indefinitely - after 2-3 recurrences despite appropriate antibiotics, FMT has superior cure rates compared to continued antibiotic cycling
• Do not use rifaximin in children <12 years without careful consideration - lacks FDA approval and pediatric dosing, though used off-label in some centers 1
• Do not assume bezlotoxumab is available - despite promising data, it was discontinued in 2025 5
• Do not skip comprehensive donor screening for FMT - risk of pathogen transmission is real and requires rigorous protocols 4

The evidence base for pediatric CDI treatment relies heavily on adult data extrapolation, with the strongest pediatric-specific guideline being the 2018 IDSA/SHEA recommendations [1-1. FMT represents the most effective human biologic therapy currently available for multiply recurrent pediatric CDI, though the evidence quality remains low due to lack of pediatric RCTs.